Foghorn Therapeutics Inc.
About Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $30.9M
- Net income
- -$74.3M
- Total assets
- $198.1M
- Market cap
- $219.0M
- Operating margin
- -279.5%
- Net margin
- -240.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $30.9M
- Operating expenses
- $117.3M
- Operating income
- -$86.4M
- Income tax
- $0
- Net income
- -$74.3M
- EPS (basic)
- $-1.18
- EPS (diluted)
- $-1.18
Balance sheet
- Total assets
- $198.1M
- Current assets
- $163.2M
- Total liabilities
- $306.6M
- Current liabilities
- $59.7M
- Shareholders’ equity
- -$108.5M
Cash flow
- Operating cash flow
- -$86.1M
- Investing cash flow
- $112.0M
- Financing cash flow
- $1.0M
- Net cash flow
- $27.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $219.0M
- EPS (diluted)
- $-1.18
- Shares outstanding
- 56.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 23, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $74.3M in FY2025.
- Revenue grew 2243% from FY2021 to FY2025.
- Trading 42% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Foghorn Therapeutics Inc..
Write a review
News about Foghorn Therapeutics Inc.
News & sentiment via Polygon.io
